{"id":"sequential-versus-triple","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL437","moleculeType":"Small molecule","molecularWeight":"255.32"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Sequential therapy involves taking antibiotics in a specific order to minimize antibiotic resistance, while triple therapy involves taking three antibiotics simultaneously. Both approaches aim to eradicate Helicobacter pylori, a common cause of stomach ulcers and gastritis.","oneSentence":"Sequential versus triple therapy is used to treat Helicobacter pylori infections by combining antibiotics to eradicate the bacteria.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:07:26.540Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of Helicobacter pylori infections"},{"name":"Eradication of H. pylori in patients with peptic ulcer disease"}]},"trialDetails":[{"nctId":"NCT06802757","phase":"PHASE2","title":"Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-05-01","conditions":"Breast Cancer","enrollment":72},{"nctId":"NCT04332848","phase":"PHASE4","title":"Susceptibility Testing Guided Versus Empirical Therapy for Refractory H. Pylori Infection","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2020-07-28","conditions":"Helicobacter Pylori Infection","enrollment":360},{"nctId":"NCT05549115","phase":"NA","title":"Susceptibility-Guided Sequential Therapy for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Liaocheng People's Hospital","startDate":"2022-09-20","conditions":"Helicobacter Pylori Infection","enrollment":500},{"nctId":"NCT00403364","phase":"PHASE2, PHASE3","title":"Sequential Therapy Versus Triple Therapy for Helicobacter Pylori Eradication: a Placebo-controlled Trial","status":"COMPLETED","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2003-07","conditions":"Helicobacter Pylori Infection","enrollment":300},{"nctId":"NCT00011986","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"Gynecologic Oncology Group","startDate":"2001-01","conditions":"Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer","enrollment":4312},{"nctId":"NCT01765582","phase":"PHASE2","title":"Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2013-01-23","conditions":"Colorectal Neoplasms","enrollment":280},{"nctId":"NCT01481844","phase":"PHASE3","title":"Sequential Therapy Versus Quadruple Therapy as Second Line Treatment After Failure of the Standard Triple Therapy for H Pylori Infection","status":"COMPLETED","sponsor":"Soroka University Medical Center","startDate":"2011-11","conditions":"Optimization of Second Line Treatment Protocol for H Pylori Eradication","enrollment":101},{"nctId":"NCT01418300","phase":"PHASE4","title":"Comparison of Conventional Triple Therapy Versus Sequential Therapy for H. Pylori in Peptic Ulcer Disease: Prospective Randomized Trial","status":"COMPLETED","sponsor":"Jun-Won Chung","startDate":"2010-08","conditions":"Helicobacter Infected Patients","enrollment":159},{"nctId":"NCT01888237","phase":"PHASE4","title":"High Dose PPI Triple Therapy Versus Sequential Therapy for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2013-05","conditions":"Dyspepsia, Helicobacter-associated Gastritis, Stomach Disorders","enrollment":118},{"nctId":"NCT02092506","phase":"PHASE4","title":"RCT: Triple vs Sequential vs Concomitant Therapy H Pylori","status":"COMPLETED","sponsor":"Changi General Hospital","startDate":"2011-12","conditions":"Bacterial Infection Due to Helicobacter Pylori (H. Pylori)","enrollment":462},{"nctId":"NCT01607918","phase":"PHASE4","title":"Clarithromycin-based Triple Therapy for 14 Days Versus Sequential Therapy 10 Days in the First Line Therapy","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2012-02","conditions":"Eradication Rates of the Two Regimens","enrollment":1300},{"nctId":"NCT01042184","phase":"PHASE4","title":"Efficacy of 10-day and 14-day Sequential Therapy Versus Triple Therapy on the Eradication of Helicobacter Pylori","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2009-12","conditions":"H. Pylori Infection","enrollment":900}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"sequential versus triple","genericName":"sequential versus triple","companyName":"Jun-Won Chung","companyId":"jun-won-chung","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sequential versus triple therapy is used to treat Helicobacter pylori infections by combining antibiotics to eradicate the bacteria. Used for Treatment of Helicobacter pylori infections, Eradication of H. pylori in patients with peptic ulcer disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}